{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:04:21Z","timestamp":1777953861015,"version":"3.51.4"},"reference-count":31,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01 FD007528"],"award-info":[{"award-number":["R01 FD007528"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019999","name":"Geoffrey Beene Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100019999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4\/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This non-randomized, open-label, phase 2 study was conducted at Memorial Sloan Kettering Cancer Center. Patients with metastatic or unresectable DDLPS, or those expected to benefit from systemic therapy prior to surgery, were eligible. Patients received palbociclib (125\u2009mg orally, days 1\u201321 of a 28-day cycle) plus retifanlimab (500\u2009mg intravenous flat dose every 4 weeks). The primary endpoint was to assess the best objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      30 patients were treated and evaluable. Median age was 61 years (range 36\u201381), 67% were male, and 63% were treatment-naive. The median follow-up was 14.8 months. ORR was 20% (95% CI 8% to 39%)\u2009and the clinical benefit rate was 53% (95% CI 34% to 72%). Median progression-free survival and overall survival were 4.8 (95% CI 1.71 to 15.7)\u2009and 27 months (95%\u2009CI 21.7 to not reached (NR)), respectively. Median duration of response was 18.4 months (95%\u2009CI 9.4 months to NR). Grade \u22653 treatment-related adverse events occurred in 61% of patients, including one Grade 4 neutropenia. There were no Grade 5 events. Retifanlimab and palbociclib were discontinued due to toxicity in 23% and 17% of patients, respectively. Tumor sequencing identified\n                      <jats:italic>JUN<\/jats:italic>\n                      amplification in 6 of 14 patients with progressive disease versus 2 patients with stable disease or partial response. Patients with progressive disease had a higher median copy number alteration burden compared with those with stable disease or partial response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Palbociclib plus retifanlimab demonstrated deep and durable responses in a subset of patients with advanced DDLPS, with an ORR exceeding that historically observed with either agent alone. Adverse events were generally manageable. Copy number alteration burden and JUN amplification merit further evaluation as potential biomarkers of resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04438824\">https:\/\/clinicaltrials.gov\/study\/NCT04438824<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014346","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:22Z","timestamp":1777914922000},"page":"e014346","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-1279","authenticated-orcid":false,"given":"Evan","family":"Rosenbaum","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Seier","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Gularte-M\u00e9rida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-5548","authenticated-orcid":false,"given":"Evan","family":"Seffar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viswatej","family":"Avutu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren B","family":"Banks","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-8544","authenticated-orcid":false,"given":"Jason E","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal M","family":"Gounder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara M","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L","family":"Keohan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-2528","authenticated-orcid":false,"given":"Robert G","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-6606","authenticated-orcid":false,"given":"Sujana","family":"Movva","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-2465","authenticated-orcid":false,"given":"Damon","family":"Reed","sequence":"additional","affiliation":[{"name":"Department on Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhoena","family":"Desir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Biniakewitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Mun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Duchemin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P","family":"Erinjeri","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Koff","sequence":"additional","affiliation":[{"name":"Sloan-Kettering Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Surgery, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-3783","authenticated-orcid":false,"given":"Sandra","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050410151450000_14.5.e014346.1","unstructured":"WCoTE B . WHO classification of tumors: soft tisse and bone tumors. 2020."},{"key":"2026050410151450000_14.5.e014346.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr485"},{"key":"2026050410151450000_14.5.e014346.3","unstructured":"P Sch\u00f6ffski RS , Martin-Broto J , Kawai A , et al . Brigimadlin vesus standard-of-care doxorubicin as first-line treatment in patients with advanced dedifferentiated liposarcoma. BRIGHTLINE-1 Presented at: Connective Tissue Oncology Society 2024 Annual Meeting; 2024"},{"key":"2026050410151450000_14.5.e014346.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"2026050410151450000_14.5.e014346.5","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"The Lancet"},{"key":"2026050410151450000_14.5.e014346.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"2026050410151450000_14.5.e014346.7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026050410151450000_14.5.e014346.8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915"},{"key":"2026050410151450000_14.5.e014346.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465"},{"key":"2026050410151450000_14.5.e014346.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.006"},{"key":"2026050410151450000_14.5.e014346.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.053"},{"key":"2026050410151450000_14.5.e014346.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1554"},{"key":"2026050410151450000_14.5.e014346.13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1540"},{"key":"2026050410151450000_14.5.e014346.14","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220729","article-title":"PD-1 blockade and CDK4\/6 inhibition augment nonoverlapping features of T cell activation in cancer","volume":"220","author":"Ali","year":"2023","journal-title":"J Exp Med"},{"key":"2026050410151450000_14.5.e014346.15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050410151450000_14.5.e014346.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11015"},{"key":"2026050410151450000_14.5.e014346.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.11511"},{"key":"2026050410151450000_14.5.e014346.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"2026050410151450000_14.5.e014346.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333"},{"key":"2026050410151450000_14.5.e014346.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00392-8"},{"key":"2026050410151450000_14.5.e014346.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6605"},{"key":"2026050410151450000_14.5.e014346.22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32117"},{"key":"2026050410151450000_14.5.e014346.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050410151450000_14.5.e014346.24","doi-asserted-by":"crossref","unstructured":"Rugo HS , Kabos P , Beck JT , et al . n.d. Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: Phase 1b study. NPJ Breast Cancer 8:118. doi:10.1038\/s41523-022-00482-2","DOI":"10.1038\/s41523-022-00482-2"},{"key":"2026050410151450000_14.5.e014346.25","article-title":"Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study","volume":"2","author":"Pujol","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2026050410151450000_14.5.e014346.26","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41388-018-0332-y","article-title":"PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4\/6 inhibitor therapy-induced senescence","volume":"37","author":"Klein","year":"2018","journal-title":"Oncogene"},{"key":"2026050410151450000_14.5.e014346.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.02.007"},{"key":"2026050410151450000_14.5.e014346.28","doi-asserted-by":"publisher","DOI":"10.1002\/path.4379"},{"key":"2026050410151450000_14.5.e014346.29","doi-asserted-by":"publisher","DOI":"10.1002\/path.2564"},{"key":"2026050410151450000_14.5.e014346.30","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Electronic address edsc, Cancer Genome Atlas Research N . Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell Nov 2017;171. doi:10.1016\/j.cell.2017.10.014","DOI":"10.1016\/j.cell.2017.10.014"},{"key":"2026050410151450000_14.5.e014346.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13286-z","article-title":"Integrated exome and RNA sequencing of dedifferentiated liposarcoma","volume":"10","author":"Hirata","year":"2019","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:25Z","timestamp":1777914925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014346"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014346","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}